Literature DB >> 3815982

Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging.

B L Shulkin, B Shapiro, I R Francis, R Dorr, S W Shen, J C Sisson.   

Abstract

I-131 metaiodobenzylguanidine (I-131 MIBG) is a well established imaging agent that reliably detects pheochromocytoma. In some patients, however, I-131 MIBG may fail to localize pheochromocytoma. I-123 MIBG has several potential advantages over I-131 MIBG, and these advantages may enable locating pheochromocytomas which have eluded other techniques, including I-131 MIBG imaging. A patient with primary extra-adrenal pheochromocytoma is described who illustrates the superiority of I-123 MIBG for the imaging of pheochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3815982     DOI: 10.1097/00003072-198612000-00012

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  5 in total

Review 1.  Diagnostic problems in pheochromocytoma.

Authors:  M Mannelli
Journal:  J Endocrinol Invest       Date:  1989-11       Impact factor: 4.256

Review 2.  Nuclear medicine and multimodality imaging of pediatric neuroblastoma.

Authors:  Wolfgang Peter Mueller; Eva Coppenrath; Thomas Pfluger
Journal:  Pediatr Radiol       Date:  2012-11-14

Review 3.  New imaging approaches to phaeochromocytomas and paragangliomas.

Authors:  Bas Havekes; Kathryn King; Edwin W Lai; Johannes A Romijn; Eleonora P M Corssmit; Karel Pacak
Journal:  Clin Endocrinol (Oxf)       Date:  2009-06-08       Impact factor: 3.478

4.  Whole Body PET Imaging with a Norepinephrine Transporter Probe 4-[18F]Fluorobenzylguanidine: Biodistribution and Radiation Dosimetry.

Authors:  Stephen J Lokitz; Sudha Garg; Rachid Nazih; Pradeep K Garg
Journal:  Mol Imaging Biol       Date:  2019-08       Impact factor: 3.488

5.  Pheochromocytoma and paraganglioma: current functional and future molecular imaging.

Authors:  Elise M Blanchet; Victoria Martucci; Karel Pacak
Journal:  Front Oncol       Date:  2012-01-06       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.